In a research report published Wednesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while reducing …
J.P.
Wednesday turned out to be a nightmare for Juno Therapeutics Inc (NASDAQ:JUNO) investors, after the drug maker disclosed that it has voluntarily placed on hold …
Juno Therapeutics Inc (NASDAQ:JUNO) reported financial results and business highlights for the third quarter 2016. “JCAR017, a key product candidate of our CD19 …
While Juno Therapeutics Inc (NASDAQ:JUNO) rides a positive tide following an abstract release from The American Society of Hematology (ASH), shares are rising …
In a research report released Thursday, FBR analyst Edward White reiterated an Outperform rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a price …
Juno Therapeutics Inc (NASDAQ:JUNO) shares rose nearly 4% today after the journal Science Translational Medicine published a paper that showed encouraging results for patients …
In a paper published in Science Translational Medicine,researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with …
In a research report released yesterday evening, BTIG analyst Dane Leone initiated coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a Sell rating …
Merrimack Pharmaceuticals Inc Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares closed down over 6% Friday, after the cancer drug maker reported second-quarter results, with net Onivyde sales …
